Standard-PCNL vs Mini-PCNL vs Super-mini PCNL for the Treatment of ≥2 cm Renal Stone
Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Dec 7, 2018
Trial Information
Current as of May 17, 2025
Unknown status
Keywords
ClinConnect Summary
BACKGROUND AND RATIONALE Percutaneous nephrolithotomy (PCNL) is the first-choice for the treatment of renal stone ≥20 mm with high stone free rate (SFR). However, there are some sever complications such as bleeding. Severe bleeding needs arterial embolization, which might impair the renal function. The size of percutaneous access tract has been proven to be closely related to the risk of bleeding complications. Mini-PCNL was firstly introduced by Jackman in 1998 to treat pediatric renal stone with the aim to lower the morbidity. Mini-PCNL was gradually applied to adults. In recent years, ur...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient ≥14 years old
- • Patient is a candidate for Standard-PCNL, Mini-PCNL or SMP treatment of a renal stone
- Exclusion Criteria:
- • Patient \<14 years old
About The First Affiliated Hospital Of Guangzhou Medical University
The First Affiliated Hospital of Guangzhou Medical University is a leading clinical research institution located in Guangzhou, China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative research. As a comprehensive teaching hospital, it integrates clinical practice, education, and research, fostering a multidisciplinary approach to healthcare. The hospital is equipped with state-of-the-art facilities and a team of experienced professionals dedicated to conducting high-quality clinical trials across various therapeutic areas. By leveraging its extensive expertise and resources, the First Affiliated Hospital aims to contribute significantly to the development of new treatments and therapies, enhancing health outcomes for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Guohua Zeng, PH.D & MD
Principal Investigator
The First Affiliated Hospital of Guangzhou Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials